, ,
Stingray Therapeutics

Lighting Up Tumors: Transforming Cancer Care with Stingray Therapeutics

About this Event

Checkpoint inhibitors like Keytruda have transformed cancer treatment, but only for a small percentage of patients because they are fighting the battle with only half an army, the adaptive immune system. Stingray Therapeutics is developing a new generation of immune-oncology drugs that unleash the power of the innate immune system, taking cancer treatment to a whole new level.

Cancers turns off innate immunity which makes it difficult for the adaptive immune system to find tumors. Stingray Therapeutics is developing SR-8541A, an oral small molecule therapeutic that reactivates the innate immune system, lighting up tumors and telling adaptive immune cells where to attack. This has the potential to significantly increase treatment efficacy up to many times current low efficacies.

Stingray is targeting four areas of medical need with its first program:
  • Metastatic microsatellite stable colorectal cancer which has just a 13% 5-year survival rate
  • Metastatic prostate cancer which affects 3.3 million people in the U.S.
  • Metastatic breast cancer, the most common female cancer in the U.S.
  • Mycobacterium avium and tuberculosis, infectious diseases that kill more than 1.3M people each year worldwide.
Watch this webinar with Stingray co-founder and CEO, Jon Northrop to hear why the NIH and Center Prevention and Research Institute of Texas backed the company with $18M in awards.

Hosted by Steven Saltzstein, CEO, Force Family Office

Video On Demand

– Recorded

April 16

SHARE THIS EVENT

All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.